GynecologyGynecology2079-56962079-5831Consilium Medicum28196Research ArticleContraceptive and therapeutic effects of drospirenone-containing hormonal antifertility agent with 24/4 dosage regimenGevorkianM Amarianagevorkyan@mail.ruManukhinI B-KuznetsovM I-SmirnovaS O-15062013153141609042020Copyright © 2013, Consilium Medicum2013This paper focuses on the use of combine hormonic contraceptive Dimia in young patients' acne treatment. It owes its effecteveness to progestin drospirenone which has high anti-androgenic activity. Prolonged treatment – by 24/4 regimen stabilizes the hormone concentration in blood due to the pituitary gonadotrophic function suppression. This dosage scheme also heightens the premenstrual syndrome and androgen dependent dermatotoses treatment efficiency.drospirenone-containing oral contraceptiveacne treatmentpremenstrual syndromeдроспиренонсодержащий оральный контрацептивлечение акнепредменструальный синдром[Вовк И.Б., Новик Л.Н., Трохимович О.В. и др. Новый оральный контрацептив с антиминералокортикоидными и антиандрогенными свойствами: эффективность и переносимость (результаты многоцентрового 6-месячного наблюдения на Украине). Гинекология. 2005; 7 (1): 44–8.][Двуреченская О.В. Сравнительное изучение антиандрогенных эффектов современных контрацептивов. Тез. докл. V Российского форума «Мать и дитя» 2003 г. М.: 2003; с. 329–30.][Кузнецова И.В., Побединский Н.М. Новый оральный контрацептив – один из многих или препарат с уникальными свойствами? Гинекология. 2004; 6 (4): 195–7.][Манухин И.Б., Тумилович Л.Г., Геворкян М.А. Клинические лекции по гинекологической эндокринологии. М.: ГЭОТАР - Медиа, 2009.][Пасман Н.М. Дроспиренон – гестаген XXI века с антиминералокортикоидной активностью. Гинекология. 2004; 6 (2): 92–6.][Apter D, Borsos A, Baumgartner W et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well - being and fluid - related symptoms. Eur J Contracept Reprod Health Care 2003; 8: 37–51.][Boschitsch E, Skarabis H, Wuttke W et al. The acceptability of novel oral contraceptive containing drospirenone and its effect on well - being. Eur J Contracept Reprod Health Care 2000; 5: 3.][De Groote D, Perrier d'Hauterive S et. al. Effects of oral contraception with ethinylestradiol and drospirenone on oxidative stress in women 18–35 years old. Contraception 2009; 80 (2): 187–93.][Foidart J.M. Added benefits of drospirenone for compliance. 11th World Congr Ginecol Endocrinol Florence, 2006. Italy, 2006; p. 10–1.][Halbreich U, Backstrom T et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for research studies. Genecol Endocrinjl 2007; 23 (3): 123–30.][Motivala A, Pitt B. Drospirenome fore Oral contraception and Hormone replacement therapy. Drugs 2007; 7(5): 47–655.][Paul G, Bell C et al. The real deal: A feasibility study of peer - led sex education for early school leavers. Contracept Reprod Health Care 2010;5 (5): 343–57.][Verchaeghe J. Hormonal contraception in women with metabolic syndsyndrome. Contracept Reprod Health Care 2010; 5 (5): 305–14.]